Hantavirus Immune Response Research: Building Assays for Mechanistic Studies

Measuring Cytokine Dysregulation in Vitro

Hantavirus-infected cells produce dramatic elevation of TNF-α, IL-6, and IL-8. These cytokines surge during innate immune recognition, creating a positive feedback loop: viral detection triggers cytokine production, which attracts more immune cells, which produce more cytokines. Building assays to measure this cascade requires tracking specific cytokines at defined timepoints across multiple strains.

Researchers setting up IL-6 quantification assays need monoclonal antibodies with validated strain specificity. From our hantavirus antibody collection, the anti-HTNV GP antibody (3G1) and anti-Puumala virus GP reference antibodies (ADI-65533, ADI-65534) provide high-specificity detection across infection timecourses. For ELISA standard curves and assay validation, recombinant antigens serve as calibration controls. Using matched antigen and antibody sets ensures consistency across experimental replicates and between researchers.

Characterizing Endothelial Cell Responses

Hantavirus infects endothelial cells without causing cytopathic effects, making them valuable for studying how infected cells alter function. Infected endothelial cells upregulate adhesion molecules (ICAM-1, VCAM-1) that recruit immune infiltrates, shift toward vasodilatory signaling, and increase tissue factor expression. This non-lytic infection model lets researchers dissect specific signaling pathways without confounding direct viral damage.

Comparative studies require strain-specific glycoproteins with consistent expression. St. John's Laboratory Gn and Gc recombinant antibodies are available across multiple strains. To compare whether ANDV and SEOV glycoproteins trigger different adhesion molecule profiles, researchers can use Anti-ANDV Gn antibody and Anti-SEOV Gn antibody, controlling for tag-related artifacts.

T Cell Exhaustion Phenotyping

Hantavirus infection triggers T cells to upregulate PD-L1/PD-L2 and express high levels of inhibitory markers including PD-1, TIM-3, and LAG-3. Characterizing these populations requires multi-parameter flow cytometry with antibodies specific to each marker and validated cross-reactivity.

Researchers building T cell phenotyping panels combine our CD marker antibodies (CD3, CD4, CD8, CD28, PD-1) with human monoclonal Puumala virus GP reference antibodies (ADI-65533/65534) to identify virus-specific T cells while mapping activation and exhaustion states. This experimental design lets investigators test whether exhaustion phenotypes emerge in specific T cell subsets or are driven by the overall inflammatory environment, and whether these patterns differ across virus strains.

Assay Development and Reproducibility

Consistent reagents are essential for developing robust assays. All St. John's Laboratory hantavirus antibodies are validated for specific platforms (ELISA, Western blot, IHC, flow cytometry, neutralisation assays) and come with application-specific dilution ranges. Recombinant proteins arrive with purity data by SDS-PAGE and are lyophilised for long-term stability, reducing batch-to-batch variation in multi-year studies.

Broad-neutralising antibodies like St. John's Laboratory anti-HTNV Gc clones (Iv0260, Iv0261) cross-react with ANDV, SEOV, PUUV, DOBV, and SNV to enable comparative assay development across strains without requiring separate antibody optimisation for each. Matching mammalian-expressed and E. coli-expressed versions of the same antigen lets researchers build parallel ELISA tracks with different cost/purity tradeoffs.

Hantavirus research is advancing our understanding of immune dysregulation at the cellular level. Robust, strain-specific reagents accelerate this progress by reducing technical variability and letting researchers focus on biology rather than reagent troubleshooting.

Explore St. John's Laboratory complete hantavirus research portfolio covering ANDV, HTNV, PUUV, SEOV, SNV, BCCV and related orthohantaviruses.

References

1. Outinen TK, et al. Viral load and humoral immune response in association with disease severity in Puumala hantavirus-infected patients. J Clin Virol. 2014;61(4):521-527.
2. Martínez VP, et al. Viral load of patients with hantavirus pulmonary syndrome in Argentina. Virus Res. 2015;210:368-372.
3. Rasmuson J, Pourazar J, Mohamed N, Lejon K, Evander M, Blomberg A, et al. Cytotoxic immune responses in the lungs correlate to disease severity in patients with hantavirus infection. Eur J Clin Microbiol Infect Dis. 2016;35(4):575–82. https://doi.org/10.1007/s10096-016-2592-1
4. Simons P, Guo Y, Bondu V, Tigert SL, Harkins M, Goodfellow S, et al. Longitudinal assessment of cytokine expression and plasminogen activation in hantavirus cardiopulmonary syndrome reveals immune regulatory dysfunction in end-stage disease. Viruses. 2021;13(8):1597. https://doi.org/10.3390/v13081597
5. Schönrich G, Krüger DH, Raftery MJ. Hantavirus-induced disruption of the endothelial barrier: neutrophils are on the payroll. Front Microbiol. 2015;6:222. https://doi.org/10.3389/fmicb.2015.00222
6. Klingström J, Smed-Sörensen A, Maleki K, Solà-Riera C, Ahlm C, Björkström N. Innate and adaptive immune responses against human Puumala virus infection: immunopathogenesis and suggestions for novel treatment strategies for severe hantavirus-associated syndromes. J Intern Med. 2019;285(5):510–23.
7. Vial PA, Ferrés M, Vial C, Klingström J, Ahlm C, López R, et al. Hantavirus in humans: a review of clinical aspects and management. Lancet Infect Dis. 2023;23(9):e371–82. https://doi.org/10.1016/S1473-3099(23)00128-7